Picture of Atossa Therapeutics logo

ATOS Atossa Therapeutics Cashflow Statement

0.000.00%
us flag iconLast trade - 00:00
HealthcareSpeculativeSmall CapNeutral

Annual cashflow statement for Atossa Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

2018
December 31st
2019
December 31st
2020
December 31st
2021
December 31st
2022
December 31st
Period Length:12 M12 M12 M12 M12 M
Source:10-K10-K10-K10-K10-K
Standards:
USG
USG
USG
USG
USG
Status:FinalFinalFinalFinalFinal
Net Income/Starting Line-11.4-17.2-17.8-20.6-27
Depreciation
Non-Cash Items2.38.636.434.837.12
Unusual Items
Other Non-Cash Items
Changes in Working Capital0.095-0.57-0.216-0.719-0.928
Change in Prepaid Expenses
Change in Other Assets
Change in Accounts Payable
Change in Accrued Expenses
Change in Other Liabilities
Cash from Operating Activities-8.96-9.13-11.6-16.5-20.8
Capital Expenditures-0.111-0.008-0.009-0.009-0.027
Purchase of Fixed Assets
Other Investing Cash Flow Items-4.7
Purchase of Investments
Cash from Investing Activities-0.111-0.008-0.009-0.009-4.73
Net Issuance / Retirement of Stock
Cash from Financing Activities12.311.338.61130
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash3.222.22796.8-25.5